Accessibility of patients with Parkinson disease to specific pharmacotherapy in Chile;Accesibilidad a la farmacoterapia específica de la enfermedad de Parkinson, en Santiago de Chile

Revista Medica de Chile

Volumn 126, Issue 11, 1998, Pages 1355-1361

  Chaná C, Pedro ^a,b   Galdames P, Daniel ^a  

^a Servicio de Psiquiatría Hospital Clínico Dr Félix Búlnes   (Chile)

^b Liga Chilena Contra el Mal Parkinson   (Chile)

Author keywords

Antiparkinson agents; Cost of illness; Parkinson disease, symptomatic; Public health

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; CHILE; ECONOMICS; FEE; FEMALE; HEALTH CARE DELIVERY; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHILE; FEES, PHARMACEUTICAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0032195562     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. CHIOFALO N, KIRSCHBAUM A, SCHOENBERG B, OLIVARES O, VALENZUELA B, SOTO E, ALVAREZ G. Estudio epidemiológico de las enfermedades neurológicas en Santiago Metropolitano, Chile Rev Chil Neuro-Psiquiat 1992; 30: 355-341.
2. OBESO JA, WEISER R, CHANÁ P, VAAMONDE J. Complicaciones evolutivas de la enfermedad de Parkinson. En Enfermedad de Parkinson: Conocimiento y actitudes prácticas. Editado por Obeso JA y Martí-Massó F. Editado por Interamericana. McGraw-Hill Madrid 1993; 57-64.
3. CHANÁ P, WEISER R, JIMÉNEZ J, OBESO JA. Origin of psychiatric complications in Parkinson's disease. Mov Disord 1994; 9(Suppl 1): S59.
4. KURTZKE JF, MURPHY FM. The changing patterns of death in parkinsonism. Neurology 1990; 40: 42-9.
5. DIAMOND SG, MARKHAM CH, HOEHN NM, MCDOWELL FH, MUENTER MDI. Multicentre study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22: 8-12.
6. UITTI RJ, AHLSKOG JE, MARAGANORE DM, MUENTER MD, ATKINSON EJ, CHA RH, O'BRIEN PC. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993; 43: 1918-26.
7. MARSDEN CD, PARKES JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1: 345-9.
8. CARANCELI T, SCIGLIANO G, MUSICCO M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991; 41: 380-4.
9. DE LONG GJ, MEERWALDT JD, SCHMITZ PIM. Factors that influence the occurrence of response variations in Parkinson disease. Ann Neurol 1987; 22: 4-7.
10. PRZUNTEK, WEIZEL D, BLUMNER E, DANIELCZYK W, LETZEL H, KAISER HJ ET AL. Bromocriptine lessens the incidence of mortality in L-dopa treated parkinsonian patients: PRADO study discontinued. Eur J Clin Pharmacol 1992; 43: 357-63.
11. RAJPUNT AH, STERN W, LAVERLY WH. Chronic lowdose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991-6.
12. FACTOR SA, SÁNCHEZ RAMOS JR, WEINER WR. Parkinson's disease: an open label trial of pergolide in patient failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988; 51: 529-33.
13. FACTOR SA, WEINER WJ. Viewpoint: Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov. Disord. 1993; 8: 257-62.
14. DODEL R, EGGERT KM, SINGER MS, EICHHORN TE, POGARELL O, OERTEL WH. Cost of Drugs Treatment in Parkinson's Disease. Mov Disord 1998; 13: 249-54.
15. PEZZOLI G, MARTIGNONI E, PACCHETTI C, ANGELERI VA, LAMBERTI P, MURATORI A ET AL. Pergolide compared with bromocriptine in Parkinson's disease: A Multicenter, Crossover, Controlled Study. Mov Disord 1994; 9: 431-6.